JP2004518709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518709A5 JP2004518709A5 JP2002563916A JP2002563916A JP2004518709A5 JP 2004518709 A5 JP2004518709 A5 JP 2004518709A5 JP 2002563916 A JP2002563916 A JP 2002563916A JP 2002563916 A JP2002563916 A JP 2002563916A JP 2004518709 A5 JP2004518709 A5 JP 2004518709A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix former
- formulation according
- formulation
- hydrophobic matrix
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims 15
- 230000002209 hydrophobic effect Effects 0.000 claims 9
- 239000007962 solid dispersion Substances 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- -1 fatty acid esters Chemical class 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000155 melt Substances 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229960003580 felodipine Drugs 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100477A SE0100477D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| SE0100478A SE0100478D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| PCT/SE2002/000228 WO2002064121A1 (en) | 2001-02-13 | 2002-02-08 | Novel modified released formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004518709A JP2004518709A (ja) | 2004-06-24 |
| JP2004518709A5 true JP2004518709A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2008-10-02 |
Family
ID=26655389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563916A Pending JP2004518709A (ja) | 2001-02-13 | 2002-02-08 | 新規放出修飾製剤 |
| JP2002563914A Pending JP2004518708A (ja) | 2001-02-13 | 2002-02-08 | 放出性が改良された新規な処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563914A Pending JP2004518708A (ja) | 2001-02-13 | 2002-02-08 | 放出性が改良された新規な処方物 |
Country Status (18)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| BR0314787A (pt) * | 2002-09-28 | 2005-07-26 | Mcneil Ppc Inc | Forma de dosagem de liberação modificada |
| SE0301904D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound II with therapeutic effect |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| EP1663313A2 (en) * | 2003-08-29 | 2006-06-07 | Dynogen Pharmaceuticals Inc. | Compositions useful for treating gastrointestinal motility disorders |
| WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| CA2549225A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| KR20060109481A (ko) * | 2003-12-04 | 2006-10-20 | 화이자 프로덕츠 인코포레이티드 | 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법 |
| SE0303451D0 (sv) * | 2003-12-18 | 2003-12-18 | Astrazeneca Ab | New compounds |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| ES2516693T3 (es) * | 2006-03-16 | 2014-10-31 | Euro-Celtique S.A. | Esferoides farmacéuticos |
| AU2009221765B2 (en) * | 2008-03-05 | 2015-05-07 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| WO2011000126A1 (zh) * | 2009-06-29 | 2011-01-06 | Liu Yu | 脂溶性药物组合物、制备方法及其用途 |
| DK2921486T3 (da) | 2009-08-07 | 2017-11-13 | American Life Science Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme |
| US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
| US20140037574A1 (en) * | 2010-11-26 | 2014-02-06 | Pius Sedowhe Fasinu | Pharmaceutical composition |
| WO2013090439A1 (en) * | 2011-12-12 | 2013-06-20 | Orbis Biosciences, Inc. | Sustained release particle formulations of guaifenesin |
| EP2790729A4 (en) * | 2011-12-12 | 2015-08-12 | Orbis Biosciences Inc | PARTICULATE FORMULATIONS WITH DELAYED RELEASE |
| EP3319595A4 (en) * | 2015-06-30 | 2019-04-03 | Kemin Industries, Inc. | ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION |
| US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| DE102017108054A1 (de) | 2017-04-13 | 2018-10-18 | Natura Werk Gebr. Hiller GmbH & Co. KG | Essbare Zusammensetzung zur Verdauungsförderung |
| EP4076527A4 (en) | 2020-01-10 | 2024-05-15 | Consynance Therapeutics, Inc. | THERAPEUTIC ACTIVE INGREDIENT COMBINATIONS AND METHODS OF USE |
| JP2024526956A (ja) | 2021-07-22 | 2024-07-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 精製ヒトｒｎａ編集酵素を使用するための組成物および方法 |
| WO2023184282A1 (en) * | 2022-03-30 | 2023-10-05 | Guizhou Sinorda Biomedicine Co., Ltd | X842 formulation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL248553A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1959-02-18 | |||
| HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
| US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
| US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
| US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
| US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
| US5851555A (en) * | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
-
2002
- 2002-02-08 NZ NZ526993A patent/NZ526993A/en unknown
- 2002-02-08 PT PT02710645T patent/PT1368006E/pt unknown
- 2002-02-08 WO PCT/SE2002/000228 patent/WO2002064121A1/en active IP Right Grant
- 2002-02-08 MX MXPA03007092A patent/MXPA03007092A/es active IP Right Grant
- 2002-02-08 IL IL15707502A patent/IL157075A0/xx unknown
- 2002-02-08 BR BR0206825-7A patent/BR0206825A/pt not_active IP Right Cessation
- 2002-02-08 CA CA002434835A patent/CA2434835A1/en not_active Abandoned
- 2002-02-08 CN CNA028049063A patent/CN1491105A/zh active Pending
- 2002-02-08 CA CA002434542A patent/CA2434542A1/en not_active Abandoned
- 2002-02-08 EP EP02711597A patent/EP1361868A1/en not_active Withdrawn
- 2002-02-08 JP JP2002563916A patent/JP2004518709A/ja active Pending
- 2002-02-08 US US10/467,723 patent/US20040067252A1/en not_active Abandoned
- 2002-02-08 DK DK02710645T patent/DK1368006T3/da active
- 2002-02-08 NZ NZ526994A patent/NZ526994A/en unknown
- 2002-02-08 CN CNA028049144A patent/CN1491104A/zh active Pending
- 2002-02-08 KR KR10-2003-7010577A patent/KR20040058103A/ko not_active Abandoned
- 2002-02-08 AU AU2002228579A patent/AU2002228579B2/en not_active Ceased
- 2002-02-08 EP EP02710645A patent/EP1368006B1/en not_active Expired - Lifetime
- 2002-02-08 ES ES02710645T patent/ES2261643T3/es not_active Expired - Lifetime
- 2002-02-08 US US10/467,900 patent/US20040067256A1/en not_active Abandoned
- 2002-02-08 DE DE60211130T patent/DE60211130T2/de not_active Expired - Fee Related
- 2002-02-08 AT AT02710645T patent/ATE324871T1/de not_active IP Right Cessation
- 2002-02-08 JP JP2002563914A patent/JP2004518708A/ja active Pending
- 2002-02-08 WO PCT/SE2002/000227 patent/WO2002064118A1/en not_active Application Discontinuation
-
2003
- 2003-08-12 NO NO20033564A patent/NO20033564L/no not_active Application Discontinuation
-
2007
- 2007-05-14 US US11/748,366 patent/US20080118560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518709A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE60129573T2 (de) | Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat | |
| EP1587497B1 (de) | Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung | |
| JP2893191B2 (ja) | 放出制御性マトリックス剤 | |
| EP1368006B1 (en) | Novel modified released formulation | |
| US9616025B2 (en) | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment | |
| AU2002228579A1 (en) | Novel modified released formulation | |
| EP1972336A1 (en) | Hot-melt micropellets | |
| KR20070119700A (ko) | 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제 | |
| US20220257772A1 (en) | Preparation of lipophilic active ingredients | |
| KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
| JP2004525887A (ja) | 新規フェノフィブラート錠剤 | |
| CN101618020A (zh) | 二氢吡啶类钙离子拮抗剂的固体自乳化口服给药系统及其制备方法 | |
| MX2007011858A (es) | Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero. | |
| JPH0530810B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CN101401788B (zh) | 联苯双酯自乳化制剂及其制备方法 | |
| WO2012035409A1 (en) | Sustained release compositions of anti-alzheimer's agents | |
| JP2010260803A (ja) | キサンタンガム被覆水溶性糖類及び圧縮成形製剤 | |
| JP5186159B2 (ja) | フェノフィブラート含有組成物 | |
| JPH0460090B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2760012B2 (ja) | 持続性細粒剤 | |
| JP2006514672A (ja) | 疎水性物質を徐放剤として含有する制御性放出製剤 | |
| JP2729494B2 (ja) | 安定な細粒剤 | |
| KR20020038591A (ko) | 경구용 의약 조성물 | |
| JP2013047282A (ja) | フェノフィブラート含有組成物 |